Boulet L P, Cowie R, Johnston P, Krakovsky D, Mark S
Hôpital Laval, Sainte-Foy, Quebec, Canada.
J Asthma. 1995;32(6):429-36. doi: 10.3109/02770909409077754.
Administration of the long-acting beta 2-adrenoceptor agonist salmeterol from a new, easy-to-operate, multidose powder inhaler (Diskus) containing 60 sealed doses in a foil strip has been compared with administration from a Diskhaler inhaler in a multicenter, double-blind, double-dummy, parallel-group study. Asthmatic patients taking anti-inflammatory treatment, with baseline FEV1 > or = 60% and < or = 90% predicted were treated for 4 weeks with salmeterol 50 micrograms twice daily from either the Diskus or Diskhaler inhaler. The two treatments were equivalent (90% CLs for the difference in mean morning PEFR: -2.2, 8.7 L/min). The Diskus inhaler was rated easier to use and was preferred by more patients than the Diskhaler inhaler (73% vs. 15%).
在一项多中心、双盲、双模拟、平行组研究中，对一种新型、易于操作的多剂量粉末吸入器（Diskus）给予长效β2肾上腺素能激动剂沙美特罗进行了比较，该吸入器在铝箔条中含有60个密封剂量，与从Diskhaler吸入器给药进行了比较。接受抗炎治疗、基线第一秒用力呼气容积（FEV1）≥预测值的60%且≤90%的哮喘患者，使用Diskus或Diskhaler吸入器，每日两次吸入50微克沙美特罗，治疗4周。两种治疗方法等效（平均早晨呼气峰流速差异的90%置信区间：-2.2，8.7升/分钟）。与Diskhaler吸入器相比，Diskus吸入器被评为使用更方便，且更受患者青睐（73%对15%）。
